Grimoire
Long-form analysis at the intersection of AI and life sciences — all spells, sorted by time.
All articles
The $0.55 Research Session: How Splitting NotebookLM and Claude Cuts Token Costs 17x
Feeding 47 papers into Claude costs $9.59 per 5-round session. Using NotebookLM for retrieval and Claude for reasoning drops that to $0.55. The secret: not a single word of your papers ever enters Claude.
If Aging Had a Master Switch: Can SIRT1 Activators Rescue the Aging Brain?
The brain slows and dulls with age. Could a drug flip a single switch and turn that around? A 2026 review puts its bet on SIRT1, the NAD⁺-dependent enzyme whose depletion in the brain is tied to cognitive decline and dementia. Promising, but still far from a human prescription.
13 Attention Mechanisms Explained: How AI Decides What to Focus On
Your Cells Are Faking Oxygen Starvation: Three Truths About the NAD⁺ Collapse
You took NMN for three months and still look the same in the mirror. Why? Three landmark studies piece together how NAD⁺ collapses with age: how cells fake hypoxia, who eats your supplements, and whether topping NAD⁺ back up can truly rejuvenate old cells.
Blood, Brain Scan, and a Human Trial: NAD⁺ Decline Finally Shows Up in Real People
We've heard plenty of mouse stories about NAD⁺ falling with age. Three studies finally move it onto real humans: a tube of blood, a brain scan, and a randomized double-blind trial each confirm NAD⁺ truly declines in us, while honestly flagging that the clinical payoff is still unsettled.